Opportunity Information: Apply for PAR 21 141
The National Institutes of Health (NIH) is offering a discretionary grant opportunity titled "AD/ADRD Clinical Trials Short Course (R25 Independent Clinical Trial Not Allowed)" under funding opportunity number PAR-21-141 (CFDA 93.866). The focus is Alzheimer s disease (AD) and Alzheimer s disease-related dementias (ADRD), with the central goal of strengthening the clinical trials workforce. NIH is explicitly looking to expand both the size and diversity of the pipeline of trained AD/ADRD clinical trialists, recognizing that the field needs more people who can design, run, and improve modern dementia-focused trials.
This program supports the development of creative, innovative short-course training programs that teach state-of-the-art clinical research and clinical trial skills specifically relevant to AD/ADRD. The intent is workforce development rather than funding a trial itself, and the mechanism is an R25 education-type grant where independent clinical trials are not allowed. In practice, that means applicants should propose training and educational experiences (for example, short courses, workshops, bootcamps, or intensive modules) that prepare participants to become effective AD/ADRD trial researchers, without proposing to lead a standalone clinical trial as the core activity of the award.
A wide range of U.S.-based organizations may apply. Eligible applicants include various levels of government (state, county, city or township, and special districts), independent school districts, public and state-controlled institutions of higher education, private institutions of higher education, federally recognized Native American tribal governments, and other Native American tribal organizations. The opportunity is also open to public housing authorities and Indian housing authorities, nonprofits with or without 501(c)(3) status (as long as they are not higher-education institutions in those categories), for-profit organizations other than small businesses, small businesses, and other eligible entities. NIH also highlights additional eligible applicants such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISI), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, regional organizations, eligible federal agencies, and U.S. territories or possessions. At the same time, the FOA makes clear that foreign participation is restricted: non-domestic (non-U.S.) entities and foreign institutions are not eligible to apply, non-domestic components of U.S. organizations are not eligible, and foreign components as defined by NIH policy are not allowed.
Key administrative details included in the source information are that NIH is the issuing agency, the funding instrument is a grant, and the activity category is health. The opportunity record shows an award ceiling of $400,000. The original closing date listed is 2023-09-07, and the FOA record was created on 2021-03-04. Overall, the grant is aimed at helping organizations build well-designed, high-impact short courses that can rapidly upskill clinicians and researchers and broaden participation in the AD/ADRD clinical trials ecosystem, ultimately improving the capacity to conduct rigorous, current, and inclusive dementia clinical research.Apply for PAR 21 141
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "AD/ADRD Clinical Trials Short Course (R25 Independent Clinical Trial Not Allowed)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.866.
- This funding opportunity was created on 2021-03-04.
- Applicants must submit their applications by 2023-09-07. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $400,000.00 in funding.
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
FAQs: AD/ADRD Clinical Trials Short Course (R25 Independent Clinical Trial Not Allowed) - PAR-21-141
1) What is this NIH funding opportunity?
This is a discretionary grant opportunity from the National Institutes of Health (NIH) titled "AD/ADRD Clinical Trials Short Course (R25 Independent Clinical Trial Not Allowed)" under funding opportunity number PAR-21-141 (CFDA 93.866). It supports the creation of short-course training programs focused on Alzheimer s disease (AD) and Alzheimer s disease-related dementias (ADRD) clinical trials skills and workforce development.
2) What is the main goal of the program?
The central goal is to strengthen the AD/ADRD clinical trials workforce. NIH is specifically looking to expand both the size and diversity of the pipeline of trained AD/ADRD clinical trialists, with an emphasis on preparing people who can design, run, and improve modern dementia-focused clinical trials.
3) What kinds of projects does NIH want to fund through this FOA?
NIH wants creative, innovative short-course training programs that teach state-of-the-art clinical research and clinical trial skills specifically relevant to AD/ADRD. Examples mentioned include short courses, workshops, bootcamps, or intensive modules designed to rapidly upskill clinicians and researchers in AD/ADRD trial methods.
4) Is this grant intended to fund an actual clinical trial?
No. The intent is workforce development and training, not funding a clinical trial as the core activity. Applicants should propose training and educational experiences that prepare participants to become effective AD/ADRD trial researchers.
5) What does "R25 Independent Clinical Trial Not Allowed" mean in practice?
It means the grant mechanism is an R25 education-type award and independent clinical trials are not allowed as the primary activity supported by the award. The application should focus on education and training (short-course experiences) rather than proposing to lead a standalone clinical trial under this award.
6) Who is the issuing agency?
The issuing agency is the National Institutes of Health (NIH).
7) What is the funding instrument and activity category?
The funding instrument is a grant, and the activity category is health.
8) What topic area does the training need to address?
The training needs to be specifically relevant to clinical research and clinical trials in Alzheimer s disease (AD) and Alzheimer s disease-related dementias (ADRD), with a focus on modern dementia-focused trial design, conduct, and improvement.
9) What types of organizations are eligible to apply?
A wide range of U.S.-based organizations may apply. Eligible applicants include:
- Government entities (state, county, city or township, and special districts)
- Independent school districts
- Public and state-controlled institutions of higher education
- Private institutions of higher education
- Federally recognized Native American tribal governments
- Other Native American tribal organizations
- Public housing authorities and Indian housing authorities
- Nonprofits with or without 501(c)(3) status (as long as they are not higher-education institutions in those categories)
- For-profit organizations other than small businesses
- Small businesses
- Other eligible entities
10) Are certain institution types specifically highlighted as eligible?
Yes. NIH highlights additional eligible applicants such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISI), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, regional organizations, eligible federal agencies, and U.S. territories or possessions.
11) Are non-U.S. (foreign) organizations eligible to apply?
No. Foreign participation is restricted. Non-domestic (non-U.S.) entities and foreign institutions are not eligible to apply.
12) Can a U.S. organization include a non-domestic component?
No. Non-domestic components of U.S. organizations are not eligible.
13) Are "foreign components" allowed under NIH policy?
No. Foreign components as defined by NIH policy are not allowed.
14) What is the award ceiling shown in the opportunity record?
The opportunity record shows an award ceiling of $400,000.
15) What is the funding opportunity number and CFDA listing?
The funding opportunity number is PAR-21-141, and the CFDA listing provided is 93.866.
16) What is the original closing date listed for this opportunity?
The original closing date listed is 2023-09-07.
17) When was the FOA record created?
The FOA record was created on 2021-03-04.
18) What kind of impact is NIH aiming for with these short courses?
The program is aimed at helping organizations build well-designed, high-impact short courses that can rapidly upskill clinicians and researchers and broaden participation in the AD/ADRD clinical trials ecosystem, ultimately improving the capacity to conduct rigorous, current, and inclusive dementia clinical research.
19) Does the FOA emphasize workforce diversity?
Yes. NIH explicitly states an interest in expanding both the size and diversity of the pipeline of trained AD/ADRD clinical trialists.
20) What kinds of learners or participants are implied to benefit from the training?
Based on the stated workforce goals, the training is intended to prepare clinicians and researchers (and other prospective trialists) to become effective AD/ADRD clinical trial researchers, with skills aligned to state-of-the-art dementia trial design and conduct.
Browse more opportunities from the same category: Health
Next opportunity: Firearm Injury and Mortality Prevention Research (R01Clinical Trial Optional)
Previous opportunity: High-throughput Discovery and Validation of Novel Signal Transducers or Small Molecules that Modulate Opioid or other Substance Use Disorder Relevant Pathways (R01 - Clinical Trials Not Allowed)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 21 141
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 21 141) also looked into and applied for these:
| Funding Opportunity |
|---|
| NIDCR Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required) Apply for PAR 21 160 Funding Number: PAR 21 160 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Limited Competition: NEI - DOD Vision Research Collaborative (R01 Clinical Trial Optional) Apply for PAR 21 161 Funding Number: PAR 21 161 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Tropical Medicine Research Centers Coordinating Center (U01 Clinical Trial Not Allowed) Apply for RFA AI 21 005 Funding Number: RFA AI 21 005 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIOSH Support for Conferences and Scientific Meetings (U13 Clinical Trial Not Allowed) Apply for PAR 21 193 Funding Number: PAR 21 193 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Tropical Medicine Research Centers (U01 Clinical Trial Not Allowed) Apply for RFA AI 21 004 Funding Number: RFA AI 21 004 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Technologies for Improving Minority Health and Eliminating Health Disparities (R41/R42- Clinical Trial Optional) Apply for RFA MD 21 005 Funding Number: RFA MD 21 005 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Innovations for Healthy Living - Improving Minority Health and Eliminating Health Disparities (R43/R44 - Clinical Trial Optional) Apply for RFA MD 21 006 Funding Number: RFA MD 21 006 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed) Apply for PAR 21 124 Funding Number: PAR 21 124 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed) Apply for PAR 21 123 Funding Number: PAR 21 123 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed) Apply for PAR 21 122 Funding Number: PAR 21 122 Agency: National Institutes of Health Category: Health Funding Amount: $499,000 |
| AHRQ/PCORI Learning Health System Small Grant Pilot Program Apply for PA 21 202 Funding Number: PA 21 202 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: Case Dependent |
| Medical Scientist Training Program (T32) Apply for PAR 21 189 Funding Number: PAR 21 189 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Mentored Career Transition Award for Intramural Fellows (K22 Clinical Trials Not Allowed) Apply for PA 21 194 Funding Number: PA 21 194 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Mentored Career Transition Award for Intramural Fellows (K22 Clinical Trials Required) Apply for PA 21 195 Funding Number: PA 21 195 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Development of Animal Models and Related Biological Materials for Research (R21 Clinical Trial Not Allowed) Apply for PAR 21 167 Funding Number: PAR 21 167 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| High-Priority Behavioral and Social Research Networks in Alzheimers Disease and Alzheimers Disease-Related Dementias (R24 Clinical Trial Optional) Apply for RFA AG 22 012 Funding Number: RFA AG 22 012 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| High-Priority Behavioral and Social Research Networks (R24 Clinical Trial Optional) Apply for RFA AG 22 013 Funding Number: RFA AG 22 013 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Research on Bat Immunology (R21 Clinical Trial Not Allowed) Apply for PAR 21 184 Funding Number: PAR 21 184 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Understanding and Modifying Temporal Dynamics of Coordinated Neural Activity (R01 Clinical Trial Optional) Apply for PAR 21 175 Funding Number: PAR 21 175 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Understanding and Modifying Temporal Dynamics of Coordinated Neural Activity (R21 Clinical Trial Optional) Apply for PAR 21 176 Funding Number: PAR 21 176 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 21 141", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.